Literature DB >> 19609744

HER2/neu expression: a predictor for differentiation and survival in children with Wilms tumor.

Seham M Ragab1, Rehab M Samaka, Tahany M Shams.   

Abstract

Wilms tumor is a mixed embroynal neoplasm of the kidney . HER2 is an onco-protein. Its over-expression could be implicated in the development of many tumors. The clinico-demographic and pathological data of 28 Wilms tumor patients were , reviewed. The tissue samples were examined by light Microscopy then immunohistochemical staining for HER2/neu expression. Additional 28 normal surrounding renal tissue specimens were included. There was significant differences between HER2/neu positive and HER2/neu negative Wilms tumors in relation to stage, histological phase and epithelial differentiation (P > 0.05 for all). The overall survival advantage was noticed if Wilms tumor was at early stages (I and II) (Log-rank = 13.23 and P > 0.001), homologous epithelial differentiation (Log-rank = 6.01 and P = 0.04), as well as HER2/neu positive tumors (Log-rank = 6.14 and P = 0.013). A statistical significant trend toward a longer recurrence free survival was, noticed if Wilms tumor was at early stages (Log-rank = 21.22, P > 0.0000) and if HER2/neu positive (Log-rank = 8.53, P = 0.004). HER2/neu expression in Wilms tumor could be a marker for epithelial and homologous differentiation and its expression could be a good predictor for overall survival and longer recurrence free survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609744     DOI: 10.1007/s12253-009-9188-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  19 in total

1.  Surgical complications after primary nephrectomy for Wilms' tumor: report from the National Wilms' Tumor Study Group.

Authors:  M L Ritchey; R C Shamberger; G Haase; J Horwitz; T Bergemann; N E Breslow
Journal:  J Am Coll Surg       Date:  2001-01       Impact factor: 6.113

Review 2.  Wilms' tumour: connecting tumorigenesis and organ development in the kidney.

Authors:  Miguel N Rivera; Daniel A Haber
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

3.  Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma.

Authors:  M A Ghanem; T H Van Der Kwast; J C Den Hollander; M K Sudaryo; R B Mathoera; M M Van den Heuvel; M A Noordzij; R J Nijman; G J van Steenbrugge
Journal:  Cancer       Date:  2001-12-15       Impact factor: 6.860

4.  Association between the HER2 expression and histological differentiation in Wilms tumor.

Authors:  M Salem; Y Kinoshita; T Tajiri; R Souzaki; K Tatsuta; M Higashi; T Izaki; K Kohashi; M Tsuneyoshi; T Taguchi
Journal:  Pediatr Surg Int       Date:  2006-11       Impact factor: 1.827

5.  Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia.

Authors:  S L Sugg; S Ezzat; L Zheng; I B Rosen; J L Freeman; S L Asa
Journal:  Clin Endocrinol (Oxf)       Date:  1998-11       Impact factor: 3.478

6.  Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).

Authors:  M J. van de Vijver
Journal:  Eur J Cancer       Date:  2001-01       Impact factor: 9.162

7.  Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.

Authors:  Hakan Bozcuk; Aziz Gumus; Gulay Ozbilim; Alpay Sarper; Ilknur Kucukosmanoglu; Irem H Ozbudak; Mehmet Artac; Mustafa Ozdogan; Mustafa Samur; Abit Kaya; Burhan Savas
Journal:  Med Sci Monit       Date:  2005-05-25

8.  Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma.

Authors:  Paolo Giovanni Nuciforo; Caterina Pellegrini; Roberta Fasani; Marco Maggioni; Guido Coggi; Antonina Parafioriti; Silvano Bosari
Journal:  Hum Pathol       Date:  2003-07       Impact factor: 3.466

9.  Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.

Authors:  L A Akslen; J E Varhaug
Journal:  Cancer       Date:  1995-11-01       Impact factor: 6.860

10.  Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms' tumor.

Authors:  Akiko Yokoi; Kimberly W McCrudden; Jianzhong Huang; Eugene S Kim; Samuel Z Soffer; Jason S Frischer; Anna Serur; Tamara New; Jenny Yuan; Mahesh Mansukhani; Kathleen O'toole; Darrell J Yamashiro; Jessica J Kandel
Journal:  J Pediatr Surg       Date:  2003-11       Impact factor: 2.545

View more
  7 in total

1.  HER2 expression in renal cell carcinoma is rare and negatively correlated with that in normal renal tissue.

Authors:  Huili Wang; Chengyi Liu; Jun Han; Lin Zhen; Tao Zhang; Xiaoli He; Enci Xu; Mengqiang Li
Journal:  Oncol Lett       Date:  2012-05-23       Impact factor: 2.967

Review 2.  Targeted immunotherapy for pediatric solid tumors.

Authors:  Lisa M Kopp; Emmanuel Katsanis
Journal:  Oncoimmunology       Date:  2015-08-31       Impact factor: 8.110

Review 3.  Biomarkers for Wilms Tumor: A Systematic Review.

Authors:  Eugene B Cone; Stewart S Dalton; Megan Van Noord; Elizabeth T Tracy; Henry E Rice; Jonathan C Routh
Journal:  J Urol       Date:  2016-05-31       Impact factor: 7.450

4.  Immunotherapy targets in pediatric cancer.

Authors:  Rimas J Orentas; Daniel W Lee; Crystal Mackall
Journal:  Front Oncol       Date:  2012-01-30       Impact factor: 6.244

Review 5.  Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.

Authors:  Nan Li; Madeline R Spetz; Dan Li; Mitchell Ho
Journal:  Pharmacol Ther       Date:  2021-05-14       Impact factor: 13.400

6.  Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic Findings.

Authors:  Mashaallah Babashahi; Mitra Mehrazma; Seyed Javad Nasiri; Farid Azizi Jalilian; Mostafa Rezaei-Tavirani
Journal:  Iran J Cancer Prev       Date:  2013

Review 7.  Immunotherapy in Pediatric Solid Tumors-A Systematic Review.

Authors:  Raoud Marayati; Colin H Quinn; Elizabeth A Beierle
Journal:  Cancers (Basel)       Date:  2019-12-14       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.